This dataset provides a comprehensive technical and clinical profile of Ketalar (Ketamine HCl) Injection USP, the gold standard for rapid-acting, non-barbiturate general anesthesia. Each 10ml multi-dose vial contains 500mg of USP-grade Ketamine Hydrochloride (50mg/mL), formulated to ensure profound analgesia and stable hemodynamics. This data is essential for researchers at NIASRA and the University of Wollongong (UOW) focused on emergency medicine, pediatric anesthesia, and NMDA receptor antagonism.
Technical Specifications
• Brand: Ketalar®
• Concentration: 50mg/mL (500mg per 10ml Multi-Dose Vial)
• CAS Number: 1867-66-9
• Regulatory Status: CIII Controlled Substance (DEA Schedule III)
• pH Range: 3.5 – 5.5 (Sterile, slightly acidic solution)
• Preservative: 0.1 mg/mL Benzethonium Chloride
Clinical & Research Applications
• General Anesthesia Induction: Investigating rapid-onset protocols for surgical procedures and trauma-related interventions.
• NMDA Receptor Antagonism: Exploring the “dissociative” state produced by blocking excitatory glutamate effects in the thalamocortical system.
• Pediatric Anesthesia: Analyzing the safety profile of ketamine for minor surgical procedures where respiratory drive maintenance is critical.
• Diagnostic Sedation: Studying its use as a sole agent for procedures not requiring skeletal muscle relaxation (e.g., dental extractions, eye/ear surgery).
Pharmacokinetics & Safety Data
• Redistribution Dynamics: Documenting the rapid distribution into highly vascularized tissues (brain/heart) followed by muscle and adipose tissue.
• Metabolic Pathways: Analyzing hepatic N-demethylation to the active metabolite norketamine.
• Emergence Phenomena: Researching the minimization of recovery-phase delirium through controlled environments and co-administration strategies.
Source Information
For authoritative clinical data and professional-grade procurement, visit:
https://lyfeunit.com/product/ketalar-ketamine-hcl-injection-usp-500mg-10ml/